Nurix Therapeutics (NASDAQ:NRIX – Get Free Report) and DiaMedica Therapeutics (NASDAQ:DMAC – Get Free Report) are both healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their risk, valuation, institutional ownership, analyst recommendations, profitability, dividends and earnings.
Institutional and Insider Ownership
10.1% of DiaMedica Therapeutics shares are held by institutional investors. 6.7% of Nurix Therapeutics shares are held by insiders. Comparatively, 5.0% of DiaMedica Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
Valuation & Earnings
This table compares Nurix Therapeutics and DiaMedica Therapeutics”s top-line revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Nurix Therapeutics | $83.98 million | 33.02 | -$264.46 million | ($3.45) | -7.74 |
| DiaMedica Therapeutics | N/A | N/A | -$32.77 million | ($0.72) | -9.06 |
DiaMedica Therapeutics has lower revenue, but higher earnings than Nurix Therapeutics. DiaMedica Therapeutics is trading at a lower price-to-earnings ratio than Nurix Therapeutics, indicating that it is currently the more affordable of the two stocks.
Analyst Recommendations
This is a summary of current ratings and recommmendations for Nurix Therapeutics and DiaMedica Therapeutics, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Nurix Therapeutics | 1 | 1 | 13 | 0 | 2.80 |
| DiaMedica Therapeutics | 1 | 0 | 4 | 0 | 2.60 |
Nurix Therapeutics presently has a consensus target price of $34.21, suggesting a potential upside of 28.05%. DiaMedica Therapeutics has a consensus target price of $12.00, suggesting a potential upside of 84.05%. Given DiaMedica Therapeutics’ higher probable upside, analysts plainly believe DiaMedica Therapeutics is more favorable than Nurix Therapeutics.
Profitability
This table compares Nurix Therapeutics and DiaMedica Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Nurix Therapeutics | -928.44% | -76.09% | -57.31% |
| DiaMedica Therapeutics | N/A | -77.76% | -69.43% |
Risk & Volatility
Nurix Therapeutics has a beta of 1.79, suggesting that its share price is 79% more volatile than the S&P 500. Comparatively, DiaMedica Therapeutics has a beta of 1.01, suggesting that its share price is 1% more volatile than the S&P 500.
Summary
Nurix Therapeutics beats DiaMedica Therapeutics on 8 of the 13 factors compared between the two stocks.
About Nurix Therapeutics
Nurix Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and cell therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications. It is also developing NX-0479/GS-6791, a IRAK4 degrader for the treatment of rheumatoid arthritis and other inflammatory diseases. The company has a strategic collaboration agreement with Gilead Sciences, Inc., Sanofi S.A., and Seagen Inc. co-development and co-commercialization for multiple drug candidates. The company was formerly known as Nurix Inc. and changed its name to Nurix Therapeutics, Inc. in October 2018. Nurix Therapeutics, Inc. was incorporated in 2009 and is headquartered in San Francisco, California.
About DiaMedica Therapeutics
DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, focuses on improving the lives of people suffering from serious diseases with a focus on acute ischemic stroke. Its lead candidate is DM199, a pharmaceutically active recombinant form of the human tissue kallikrein-1 protein, which is in Phase II/III trials for the treatment of acute ischemic stroke, as well as that is in Phase 2 to treat cardio-renal disease. The company also develops DM300, which is in preclinical stage for the treatment of severe inflammatory diseases. In addition, it develops treatment for neurological disease. The company was formerly known as DiaMedica Inc. and changed its name to DiaMedica Therapeutics Inc. in December 2016. DiaMedica Therapeutics Inc. was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.
Receive News & Ratings for Nurix Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nurix Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
